Rating Change
JP Morgan analysts reiterated a Neutral rating on Alkermes plc (NASDAQ:ALKS) on July 13, 2026.
reiterateNASDAQ:ALKS
JP Morgan Reiterates Neutral Rating on Alkermes plc (ALKS)
Rating Change JP Morgan analysts reiterated a Neutral rating on Alkermes plc (NASDAQ:ALKS) on July 13, 2026. Market Context Alkermes plc operates in the Healthcare sector. The…
Market Context
Alkermes plc operates in the Healthcare sector. The stock currently trades at $51.87 with a market capitalization of $5.0B. The stock has gained 77.9% over the past 52 weeks.
Analyst coverage from JP Morgan provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Alkermes plc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Alkermes plc
Among the 10 most recent ratings: 8 Buy, 1 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 13, 2026 | Needham | Buy | N/A |
| Jul 13, 2026 | JP Morgan | Neutral | N/A |
| Jul 02, 2026 | Mizuho | Outperform | N/A |
| Jun 29, 2026 | Wells Fargo | Overweight | N/A |
| Jun 29, 2026 | B of A Securities | Underperform | N/A |
Related Tools: Analyst Ratings Dashboard | View ALKS Stock Page
Frequently Asked Questions
What does a Neutral rating mean for ALKS?
A Neutral rating from JP Morgan reflects the analyst's outlook on Alkermes plc (NASDAQ:ALKS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ALKS forecast page.